BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 177
- Registration Number
- NCT04089839
- Locations
- 🇫🇷
Local Institution, Paris, France
An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT04086719
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- Interventions
- Biological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT04088500
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis WUSTL, Saint Louis, Missouri, United States
🇨🇦Local Institution, Quebec City, Quebec, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04082741
- Locations
- 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
- Conditions
- CancerBreast Cancer
- Interventions
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT04075604
- Locations
- 🇺🇸
The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States
🇺🇸MetroHealth Medical Center, Cleveland, Ohio, United States
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
- Conditions
- Healthy ParticipantsIdiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Diagnostic Test: 18F-BMS-986327
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14
- Registration Number
- NCT04069143
- Locations
- 🇺🇸
Local Institution - 0001, New Haven, Connecticut, United States
A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets
- Conditions
- Lupus
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT04065932
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT04055506
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
A Study of Nivolumab in Patients With Head and Neck Cancer.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 502
- Registration Number
- NCT04050761
- Locations
- 🇫🇷
Local Institution - 0001, Paris, France
A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 260
- Registration Number
- NCT04045639
- Locations
- 🇬🇧
Local Institution, Worcester, United Kingdom